Table 5.
Medication characteristics and effect on weight loss, all patients - unadjusted analyses.
| Medication | Medication Instances, n (%) | Instances with complete weight information, n (%)¥ | Pre-medication BMI, kg/m2 mean (95% CI) | Duration of use, years mean (95% CI) | Maximum weight loss, %TBW mean (95% CI)‡ |
Final weight loss, %TBW mean (95% CI)‡ |
|---|---|---|---|---|---|---|
| Young adults (19–25 years old) | ||||||
| Metformin | 489 (32.7) | 239 (48.9) | *42.1 (41.2–43.1) | *2.50 (2.0–3.0) | 3.42 (2.6–4.3) | −0.39 (−1.5–0.7) |
| Topiramate | 378 (25.3) | 166 (43.9) | *38.0 (37.0–39.0) | 2.18 (1.9–2.4) | 3.98 (2.9–5.0) | 0.34 (−1.1–1.7) |
| Bupropion | 370 (24.7) | 146 (39.5) | *37.5 (36.4–38.7) | 2.24 (2.0–2.5) | 2.44 (1.0–3.8) | *-2.88 (−4.4–1.3) |
| Phentermine | 142 (9.5) | 75 (52.8) | *41.5 (39.7–43.3) | 0.84 (−0.9–2.5) | 4.42 (3.1–5.8) | *1.17 (−0.3–2.6) |
| Zonisamide | 32 (2.1) | 7 (21.9) | 39.1 (31.9–46.2) | 1.93 (1.2–2.7) | 5.03 (−1.8–11.8) | −4.87 (−10.9–1.1) |
| Naltrexone | 39 (2.6) | 13 (33.3) | *32.8 (29.6–36.0) | *1.02 (0.5–1.5) | 3.13 (0.8–5.5) | 0.76 (−2.1–3.6) |
| Orlistat | 23 (1.5) | 13 (56.5) | 40.9 (37.7–44.2) | *0.76 (0.4–1.1) | *0.90 (−0.5–2.3) | −2.24 (−4.8–0.3) |
| Liraglutide | 23 (1.5) | 6 (26.1) | 44.7 (38.7–50.7) | *1.03 (0.5–1.5) | 3.52 (2.1–5.0) | *0.69 (−0.5–1.9) |
| Overall | 1,496 (100.0) | 665 (44.5) | 39.8 (39.3–40.4) | 2.10 (1.8–2.3) | 3.42 (2.9–4.0) | −0.63 (−1.3–0.0) |
| Adolescents (13–18 years old) | ||||||
| Metformin | 283 (45.4) | 159 (56.2) | *2.42 (2.4–2.5) | *2.55 (2.3–2.8) | *0.07 (0.0–0.1) | −0.01 (0.0–0.0) |
| Topiramate | 156 (25.0) | 66 (42.3) | *2.19 (2.1–2.3) | 2.22 (1.9–2.6) | 0.14 (0.1–0.2) | *-0.08 (−0.1–0.0) |
| Bupropion | 123 (19.7) | 45 (36.6) | *2.15 (2.0–2.3) | 2.09 (1.7–2.5) | 0.09 (0.0–0.2) | −0.04 (−0.2–0.1) |
| Phentermine | 47 (7.5) | 23 (48.9) | 2.36 (2.2–2.5) | *1.82 (1.3–2.3) | *0.24 (0.1–0.4) | *0.12 (0.0–0.2) |
| Zonisamide | 15 (2.4) | 6 (40.0) | 2.15 (1.9–2.4) | 1.74 (0.2–3.3) | *-0.08 (−0.3–0.1) | *-0.08 (−0.1–0.1) |
| Overall | 624 (100.0) | 299 (47.9) | 2.32 (2.3–2.4) | 2.30 (2.1–2.5) | 0.09 (0.1–0.1) | −0.02 (0.0–0.0) |
| Children (5–12 years old) | ||||||
| Metformin | 41 (45.6) | 17 (41.5) | 2.50 (2.4–2.6) | 2.75 (2.0–3.5) | 0.03 (0.0–0.1) | −0.06 (−0.2–0.0) |
| Topiramate | 33 (36.7) | 17 (51.5) | 2.39 (2.3–2.5) | 2.64 (1.8–3.5) | 0.11 (0.0–0.2) | 0.01 (−0.1–0.2) |
| Bupropion | 16 (17.8) | 7 (43.8) | *2.21 (2.0–2.4) | 2.70 (1.2–4.2) | 0.08 (0.0–0.1) | −0.07 (−0.3–0.1) |
| Overall | 90 (100.0) | 41 (45.6) | 2.42 (2.3–2.5) | 2.70 (2.2–3.2) | 0.06 (0.0–0.1) | −0.04 (−0.1–0.0) |
*
Statistically significant difference when compared to the overall frequency-weighted mean, p < 0.05.
¥
Complete weight information indicates patients with both start and end weights recorded in chart. ‡Negative weight loss indicates weight gain.